PubRank

H Kalervo Väänänen

Author PubWeight™ 61.09‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Serum osteocalcin is not associated with glucose but is inversely associated with leptin across generations of nondiabetic women. J Clin Endocrinol Metab 2012 1.49
2 Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 2002 1.46
3 Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 2002 1.38
4 Isolated primary osteocytes express functional gap junctions in vitro. Cell Tissue Res 2005 1.36
5 Conditioned medium from osteocytes stimulates the proliferation of bone marrow mesenchymal stem cells and their differentiation into osteoblasts. Exp Cell Res 2004 1.28
6 Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption. Clin Lab 2006 1.22
7 Osteocytes inhibit osteoclastic bone resorption through transforming growth factor-beta: enhancement by estrogen. J Cell Biochem 2002 1.22
8 Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis). Clin Chem 2004 1.17
9 Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 2003 1.16
10 Intracellular machinery for matrix degradation in bone-resorbing osteoclasts. J Bone Miner Res 2004 1.15
11 Osteoclast ruffled border has distinct subdomains for secretion and degraded matrix uptake. Traffic 2003 1.14
12 The critical role of IL-34 in osteoclastogenesis. PLoS One 2011 1.14
13 FGF-8 is involved in bone metastasis of prostate cancer. Int J Cancer 2008 1.13
14 Intracellular membrane trafficking in bone resorbing osteoclasts. Microsc Res Tech 2003 1.13
15 Estrogen and testosterone use different cellular pathways to inhibit osteoclastogenesis and bone resorption. J Bone Miner Res 2005 1.12
16 Associations between homocysteine, bone turnover, BMD, mortality, and fracture risk in elderly women. J Bone Miner Res 2007 1.11
17 Release of intact and fragmented osteocalcin molecules from bone matrix during bone resorption in vitro. J Biol Chem 2004 1.11
18 Death of osteocytes turns off the inhibition of osteoclasts and triggers local bone resorption. Biochem Biophys Res Commun 2005 1.11
19 Monocyte-macrophage system as a target for estrogen and selective estrogen receptor modulators. Ann N Y Acad Sci 2006 1.06
20 Possible role of direct Rac1-Rab7 interaction in ruffled border formation of osteoclasts. J Biol Chem 2005 1.01
21 Bone turnover markers and prediction of fracture: a prospective follow-up study of 1040 elderly women for a mean of 9 years. J Bone Miner Res 2010 0.99
22 Breast cancer cells with inhibition of p38alpha have decreased MMP-9 activity and exhibit decreased bone metastasis in mice. Clin Exp Metastasis 2004 0.98
23 Membrane-bound carbonic anhydrases in osteoclasts. Bone 2006 0.98
24 Bone marrow cell differentiation induced by mechanically damaged osteocytes in 3D gel-embedded culture. J Bone Miner Res 2006 0.97
25 Human mesenchymal stem cell derived osteoblasts degrade organic bone matrix in vitro by matrix metalloproteinases. Matrix Biol 2005 0.96
26 Serial assessment of serum bone metabolism markers identifies women with the highest rate of bone loss and osteoporosis risk. J Clin Endocrinol Metab 2008 0.95
27 Biochemical markers of bone turnover are influenced by recently sustained fracture. Bone 2005 0.93
28 Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 2005 0.93
29 Regulation of osteoblast differentiation: a novel function for fibroblast growth factor 8. Endocrinology 2006 0.92
30 Intracellular membrane trafficking pathways in bone-resorbing osteoclasts revealed by cloning and subcellular localization studies of small GTP-binding rab proteins. Biochem Biophys Res Commun 2002 0.92
31 Estrogen responsiveness of bone formation in vitro and altered bone phenotype in aged estrogen receptor-alpha-deficient male and female mice. Eur J Endocrinol 2005 0.91
32 Evidence for the role of osteocytes in the initiation of targeted remodeling. Technol Health Care 2009 0.91
33 Transient 100 nM dexamethasone treatment reduces inter- and intraindividual variations in osteoblastic differentiation of bone marrow-derived human mesenchymal stem cells. Tissue Eng Part C Methods 2012 0.91
34 Receptor tyrosine kinase inhibition causes simultaneous bone loss and excess bone formation within growing bone in rats. Toxicol Appl Pharmacol 2011 0.91
35 Overexpression of vascular endothelial growth factor C increases growth and alters the metastatic pattern of orthotopic PC-3 prostate tumors. BMC Cancer 2009 0.89
36 RNA interference tolerates 2'-fluoro modifications at the Argonaute2 cleavage site. Chem Biodivers 2007 0.89
37 Estrogen and the selective estrogen receptor modulator (SERM) protection against cell death in estrogen receptor alpha and beta expressing U2OS cells. Mol Cell Endocrinol 2008 0.88
38 The effects of tamoxifen and toremifene on bone cells involve changes in plasma membrane ion conductance. J Bone Miner Res 2003 0.88
39 Inhibition of the osteoclast V-ATPase by small interfering RNAs. FEBS Lett 2005 0.88
40 Phosphatase and oxygen radical-generating activities of mammalian purple acid phosphatase are functionally independent. Biochem Biophys Res Commun 2002 0.88
41 Urinary osteocalcin as a marker of bone metabolism. Clin Chem 2005 0.88
42 Potential function for the ROS-generating activity of TRACP. J Bone Miner Res 2003 0.87
43 Macrophages overexpressing tartrate-resistant acid phosphatase show altered profile of free radical production and enhanced capacity of bacterial killing. Biochem Biophys Res Commun 2005 0.86
44 A rationale for osteoclast selectivity of inhibiting the lysosomal V-ATPase a3 isoform. Calcif Tissue Int 2010 0.86
45 FGF-8b induces growth and rich vascularization in an orthotopic PC-3 model of prostate cancer. J Cell Biochem 2009 0.86
46 Overexpression of cathepsin K accelerates the resorption cycle and osteoblast differentiation in vitro. Bone 2008 0.86
47 Pharmacological sequestration of intracellular cholesterol in late endosomes disrupts ruffled border formation in osteoclasts. J Bone Miner Res 2005 0.86
48 Cystatin B as an intracellular modulator of bone resorption. Matrix Biol 2006 0.86
49 Degradation of hydroxyapatite in vivo and in vitro requires osteoclastic sodium-bicarbonate co-transporter NBCn1. Matrix Biol 2010 0.86
50 The architecture of microtubular network and Golgi orientation in osteoclasts--major differences between avian and mammalian species. Exp Cell Res 2003 0.84
51 Bisphosphonate induced growth inhibition of breast cancer cells is augmented by p38 inhibition. Breast Cancer Res Treat 2003 0.83
52 Improved methods for testing antiresorptive compounds in human osteoclast cultures. J Bone Miner Metab 2008 0.82
53 Rab13 is upregulated during osteoclast differentiation and associates with small vesicles revealing polarized distribution in resorbing cells. J Histochem Cytochem 2012 0.81
54 Sequence and TLR9 independent increase of TRACP expression by antisense DNA and siRNA molecules. Biochem Biophys Res Commun 2007 0.81
55 Tumor necrosis factor-alpha induces interleukin-6 production via extracellular-regulated kinase 1 activation in breast cancer cells. Breast Cancer Res Treat 2003 0.81
56 Recombinant VSV G proteins reveal a novel raft-dependent endocytic pathway in resorbing osteoclasts. Exp Cell Res 2008 0.80
57 Effects of proteolysis and reduction on phosphatase and ROS-generating activity of human tartrate-resistant acid phosphatase. Arch Biochem Biophys 2006 0.79
58 Analysis by siRNA_profile program displays novel thermodynamic characteristics of highly functional siRNA molecules. Source Code Biol Med 2008 0.78
59 Tartrate-resistant acid phosphatase 5B circulates in human serum in complex with alpha2-macroglobulin and calcium. Biochem Biophys Res Commun 2003 0.78
60 Novel perspectives on the transcytotic route in osteoclasts. Bonekey Rep 2013 0.78
61 Identification of novel proteolytic forms of osteocalcin in human urine. Biochem Biophys Res Commun 2003 0.77
62 Overexpression of human hydroxysteroid (17beta) dehydrogenase 2 induces disturbance in skeletal development in young male mice. J Bone Miner Res 2008 0.76
63 Skeletal changes in transgenic male mice expressing human cytochrome p450 aromatase. J Bone Miner Res 2004 0.76
64 Urinary osteocalcin and serum pro-C-type natriuretic peptide predict linear catch-up growth in infants. J Bone Miner Res 2012 0.76
65 Urinary osteocalcin is a useful marker for monitoring the effect of alendronate therapy. Clin Chem 2005 0.75
66 Clinical performance of six different serum tartrate-resistant acid phosphatase assays for monitoring alendronate treatment. Clin Lab 2008 0.75